Business Wire

Zero Networks Boosts International Sales Capabilities With Key EMEA Hire

21.7.2025 10:00:00 CEST | Business Wire | Press Release

Share

Zero Networks, a leader in zero trust security solutions, today announced the appointment of Tony Hadzima as Vice President of Sales for EMEA and LATAM. This strategic hire supports the company’s global expansion goals and rising demand for its innovative microsegmentation and zero trust offerings.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250721956495/en/

Tony Hadzima joins Zero Networks as Vice President, Sales EMEA & LATAM

Hadzima brings nearly 30 years of international sales and business leadership experience. He spent 15 years at Palo Alto Networks, where he became the company’s first employee in Spain and its 126th worldwide. He held and grew into multiple leadership roles: Country Manager of Iberia, VP South Europe, and VP EMEA & LATAM for Smart Industries OT/IoT Security. Under Hadzima’s leadership, he built top-performing teams from scratch, achieving some of the highest market shares and biggest wins in EMEA.

In June 2025, Zero Networks announced $55 million of Series C funding to fuel the company’s next phase of growth, including team expansion across sales and marketing, research and development, and customer support. Additionally, funding has been earmarked for go-to-market investments in North America, EMEA, and APAC and to support continued innovation in Zero Networks’ award-winning solutions.

“I feel privileged to join a company like Zero Networks to disrupt a mature market ripe for innovation,” said Hadzima. “Zero Networks brings a radical new approach to solving complex customer challenges like ransomware prevention and microsegmentation without the operational burden, all in record time. I’m energized to build a world-class team, scale with our partners, and elevate our EMEA and LATAM teams to the next level in this time of accelerated growth!”

“We’re thrilled to welcome Tony to the team,” said Scott Coffey, VP of Sales at Zero Networks. “Cybersecurity is a reputation-driven industry, and Tony is one of the most trusted leaders in the space. His track record speaks for itself. Together with our recent product and engineering investments, his arrival reinforces our commitment to delivering exceptional zero trust outcomes to customers around the globe.”

Zero Networks is on a mission to modernize microsegmentation with enterprise-grade solutions that are simple to deploy, highly effective at stopping ransomware and insider threats, and purpose-built to meet regulatory and cyber insurance demands.

Learn more about Zero Networks at zeronetworks.com.

About Zero Networks

Zero Networks is revolutionizing network security with its effortless microsegmentation solution that stops ransomware and implements in days, not years. By automating asset tagging and policy creation, Zero Networks saves enterprises an average of 86% on total cost of ownership compared to legacy microsegmentation solutions that rely on time-intensive manual processes. Combined with advanced Identity Segmentation and Zero Trust Network Access solutions, and fortified by network-layer MFA, Zero Networks’ platform accelerates zero trust initiatives at companies of any size. This comprehensive approach enables organizations to stop lateral movement attacks, exceed compliance requirements, achieve top-tier audit scores, and pass every penetration test. For more information, visit zeronetworks.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250721956495/en/

Contacts

Media Contact
Rose Ross
Omarketing
rose@omarketing.com
+44 7976 154 597

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye